127
Participants
Start Date
October 26, 2022
Primary Completion Date
December 27, 2023
Study Completion Date
April 18, 2024
Lirentelimab (AK002)
Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
Placebo
Placebo
Allakos Investigational Site 227-007, Great Neck
Allakos Investigational Site 227-022, Brooklyn
Allakos Investigational Site 227-201, Berlin
Allakos Investigational Site 227-028, Hershey
Allakos Investigational Site 227-040, Philadelphia
Allakos Investigational Site 227-063, White Marsh
Allakos Investigational Site 227-012, Towson
Allakos Investigational Site 227-019, Baltimore
Allakos Investigational Site 227-214, Buxtehude
Allakos Investigational Site 227-002, Asheville
Allakos Investigational Site 227-066, North Charleston
Allakos Investigational Site 227-018, Columbus
Allakos Investigational Site 227-036, Jacksonville
Allakos Investigational Site 227-062, Miami
Allakos Investigational Site 227-067, Tampa
Allakos Investigational Site 227-005, Tampa
Allakos Investigational Site 227-041, Sarasota
Allakos Investigational Site 227-068, Cullman
Allakos Investigational Site 227-024, Birmingham
Allakos Investigational Site 227-051, Lexington
Allakos Investigational Site 227-043, Columbus
Allakos Investigational Site 227-064, Toledo
Allakos Investigational Site 227-013, Cincinnati
Allakos Investigational Site 227-029, Cincinnati
Allakos Investigational Site 227-074, Plainfield
Allakos Investigational Site 227-034, Ann Arbor
Allakos Investigational Site 227-032, Detroit
Allakos Investigational Site 227-070, Farmington Hills
Allakos Investigational Site 227-206, Osnabrück
Allakos Investigational Site 227-033, Greenfield
Allakos Investigational Site 227-210, Mainz
Allakos Investigational Site 227-202, Mainz
Allakos Investigational Site 227-052, Rochester
Allakos Investigational Site 227-073, Dilworth
Allakos Investigational Site 227-059, Missoula
Allakos Investigational Site 227-057, River Forest
Allakos Investigational Site 227-208, Frankfurt
Allakos Investigational Site 227-045, Normal
Allakos Investigational Site 227-008, St Louis
Allakos Investigational Site 227-205, Darmstadt
Allakos Investigational Site 227-047, Overland Park
Allakos Investigational Site 227-060, Oklahoma City
Allakos Investigational Site 227-055, Austin
Allakos Investigational Site 227-049, El Paso
Allakos Investigational Site 227-211, Munich
Allakos Investigational Site 227-006, Colorado Springs
Allakos Investigational Site 227-045, Boise
Allakos Investigational Site 227-039, Murray
Allakos Investigational Site 227-071, Murray
Allakos Investigational Site 227-014, Phoenix
Allakos Investigational Site 227-023, Scottsdale
Allakos Investigational Site 227-204, Augsburg
Allakos Investigational Site 227-207, Langenau
Allakos Investigational Site 227-026, Los Angeles
Allakos Investigational Site 227-009, Los Angeles
Allakos Investigational Site 227-021, Santa Monica
Allakos Investigational Site 227-209, Erlangen
Allakos Investigational Site 227-031, Upland
Allakos Investigational Site 227-011, Mission Viejo
Allakos Investigational Site 227-058, Bakersfield
Allakos Investigational Site 227-027, Portland
Allakos Investigational Site 227-016, Boston
Allakos Investigational Site 227-203, Leipzig
Allakos Investigational Site 227-302, Lodz
Allakos Investigational Site 227-304, Lodz
Allakos Investigational Site 227-303, Lublin
Allakos Investigational Site 227-301, Zabrze
Lead Sponsor
Allakos Inc.
INDUSTRY